GIT1 Knockout Mouse Model for ADHD Drug Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current ADHD models, such as spontaneous hypertensive rats and dopamine transporter knockout mice, have limitations in demonstrating the pathogenic causes of attention deficit hyperactivity disorder (ADHD) and do not adequately address the need for novel drug screening methods that can effectively treat ADHD symptoms without causing significant side effects.
Innovation Solution
The use of GIT1 knockout mice as an animal model, which exhibit ADHD symptoms, allows for a comprehensive approach combining molecular biology, cellular biology, and animal behavior studies, along with electroencephalogram analysis, to screen for novel drugs that can recover ADHD symptoms and improve theta brain waves in the frontal lobe.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing ADHD animal models (SHR, DAT-KO mice) are used, then ADHD symptoms can be observed, but the pathogenic causes of ADHD cannot be adequately demonstrated
Solution Approach 1:
The patent extracts and eliminates the limitations of existing ADHD models by creating a novel GIT1 knockout mouse model. This new model specifically targets the GIT1 gene, which is associated with ADHD pathogenesis, thereby extracting the core pathogenic mechanism while removing the inability to demonstrate clear pathogenic causes that plagues existing models.
Solution Approach 2:
The patent changes the fundamental parameter of the animal model from dopamine transporter deficiency (DAT-KO) or hypertension (SHR) to GIT1 gene knockout. This parameter change enables the model to specifically demonstrate GIT1's role in ADHD pathogenesis while maintaining ADHD symptoms, thereby resolving the contradiction between model reliability and drug screening versatility.
2Productivity
If novel drugs are screened using existing models, then potential treatments can be identified, but side effects cannot be adequately assessed
Solution Approach 1:
The patent implements a comprehensive feedback system that monitors multiple parameters including ADHD symptoms, theta brain wave activity, and side effects simultaneously. This multi-parameter feedback enables early detection of both therapeutic effects and adverse reactions, allowing for more accurate assessment of novel drug candidates before clinical trials.
Solution Approach 2:
The GIT1 knockout mouse model serves multiple functions: it demonstrates ADHD symptoms, allows theta brain wave analysis, and enables side effect monitoring. This multi-functional model increases productivity in drug screening while simultaneously providing comprehensive safety assessment, thereby resolving the contradiction between drug identification efficiency and side effect evaluation.
3Measurement precision
If comprehensive analysis (molecular biology, cellular biology, EEG) is performed, then accurate ADHD mechanism understanding is achieved, but study complexity increases
Solution Approach 1:
The patent segments the comprehensive analysis into distinct modular components: molecular biology analysis of GIT1 expression, cellular biology studies of neuronal function, and EEG analysis of theta brain waves. Each module can be independently optimized and performed by specialized teams, thereby achieving high measurement precision while managing study complexity through systematic division of labor.
Data Source
AI summary
Provided is a method of using any mammal except humans, in particular, a mammal as an attention deficit hyperactivity disorder model, wherein genes of G protein-coupled receptor kinase interacting protein 1 (GIT1) as a neuronal synapse protein in the brain are knocked out from the mammal. In addition, disclosed is analysis of GIT1 knock-out mice in aspects of molecular biology, cellular biology, electrical biology and animal behavior and, more particularly, a screening method of novel drug, wherein excessive behavior as an attention deficit hyperactive disorder as well as recovery of theta wave in the frontal lobe are observed by administering a candidate material of the drug, thereby inducing recovery of the attention deficit hyperactivity disorder.